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BACKGROUND & AIMS: Severe forms of inﬂammatory bowel
disease (IBD) that develop in very young children can be
caused by variants in a single gene. We performed whole-
exome sequence (WES) analysis to identify genetic factors
that might cause granulomatous colitis and severe perianal
disease, with recurrent bacterial and viral infections, in an
infant of consanguineous parents. METHODS: We performed
targeted WES analysis of DNA collected from the patient and
her parents. We validated our ﬁndings by a similar analysis of
DNA from 150 patients with very-early-onset IBD not associ-
ated with known genetic factors analyzed in Toronto, Oxford,
and Munich. We compared gene expression signatures in*Authors share co-ﬁrst authorship; §Authors share co-senior authorship.
Abbreviations used in this paper: eQTL, expression quantitative trait loci;
GWAS, genome-wide association study; MDP, muramyl dipeptide; NF-kB,
nuclear factorLkB; NOD2, nucleotide binding oligomerization domain
containing 2; RSV, to respiratory syncytial virus; TNF, tumor necrosisinﬂamed vs noninﬂamed intestinal and rectal tissues collected
from patients with treatment-resistant Crohn’s disease who
participated in a trial of ustekinumab. We performed func-
tional studies of identiﬁed variants in primary cells from
patients and cell culture. RESULTS: We identiﬁed a homozy-
gous variant in the tripartite motif containing 22 gene
(TRIM22) of the patient, as well as in 2 patients with a disease
similar phenotype. Functional studies showed that the variant
disrupted the ability of TRIM22 to regulate nucleotide binding
oligomerization domain containing 2 (NOD2)dependent
activation of interferon-beta signaling and nuclear factorkB.
Computational studies demonstrated a correlation between
the TRIM22NOD2 network and signaling pathways and ge-
netic factors associated very early onset and adult-onset IBD.
TRIM22 is also associated with antiviral and mycobacterialfactor; TRIM22, tripartite motif containing 22 gene; VEOIBD, Very-early
onset inﬂammatory bowel diseases; WES, whole exome sequencing.
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May 2016 Variants in TRIM22 and Very-Early-Onset IBD 1197effectors and markers of inﬂammation, such as fecal calpro-
tectin, C-reactive protein, and Crohn’s disease activity index
scores. CONCLUSIONS: In WES and targeted exome sequence
analyses of an infant with severe IBD characterized by gran-
ulomatous colitis and severe perianal disease, we identiﬁed a
homozygous variant of TRIM22 that affects the ability of its
product to regulate NOD2. Combined computational and
functional studies showed that the TRIM22-NOD2 network
regulates antiviral and antibacterial signaling pathways that
contribute to inﬂammation. Further study of this network
could lead to new disease markers and therapeutic targets for
patients with very early and adult-onset IBD.
Keywords: VEOIBD; NF-kB; Antiviral and Antibacterial
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disease that is difﬁcult to treat with conventional therapies.
These young patients frequently have novel causal1–3 and
risk variants4–8 and common networks are now being
established (reviewed in Uhlig et al9). For example, muta-
tions in IL10RA/B genes cause a Mendelian form of VEOIBD
with severe colitis and perianal disease10 and mutations in
TTC7A cause a severe form of apoptotic enterocolitis.1
Tripartite motif-containing 22 (TRIM22; also known as
STAF50) is a RING ﬁnger E3 ubiquitin ligase11 that is
expressed in the intestine12 and in macrophages,13 and has a
role in lineage-speciﬁc differentiation of lymphocytes.14
TRIM22 was originally identiﬁed as an interferon inducible
protein that possesses antiviral activity15–17 and activates
nuclear factorkB (NF-kB) signaling.13 Here we identify
TRIM22 functional variants associated with a distinct
VEOIBD phenotype characterized by granulomatous colitis
and severe perianal disease and show the TRIM22-NOD2
network as a key antiviral and mycobacterial regulator.Materials and Methods
See Supplementary Material for full methods information.
Subjects
All experiments were carried out with the approval of the
Research Ethics Board at the Hospital for Sick Children.
Informed consent to participate in research was obtained. A
copy of the consent is available on the NEOPICS (International
Early Onset Pediatric IBD Cohort Study) website (http://www.
neopics.org/NEOPICS_Documents.html).
Whole Exome Sequencing
For patient 1 and her parents (trio), whole exome
sequencing (WES) was performed using the Agilent SureSelect
Human All Exon 50-Mb kit with high-throughput sequencing
conducted using the SOLiD 4 System at The Center for Applied
Genomics through the Hospital for Sick Children (Toronto).
Sanger sequencing was used to verify variant genotypes in
family 1 and infantile patients from the collaborating in-
stitutions were screened for TRIM22 variants.Validation
In order to validate these ﬁndings, we examined WES re-
sults from 150 infantile international VEOIBD patients without
a genetic diagnosis who were previously sequenced in Toronto
(NEOPICS), Oxford, and Munich (Care for Rare) and targeted
exome sequencing of the TRIM22 gene in 10 IL10RA/B, and
IL10-negative patients without previous WES.Computational Analysis
Datasets. Biopsy data were collected at baseline from
antitumor necrosis factor (TNF)-resistant Crohn’s patients
enrolled in the ustekinumab trial described previously.18 The
ustekinumab trial expression data were used for construction
of the adult IBD network. RNA-seq from the RISK cohort, as
described previously,19 was used for generation of the pediatric
IBD Bayesian network.
Differential expression. To ascertain tissue-speciﬁc
signatures, we examined inﬂamed vs noninﬂamed tissue from
various anatomic regions of the small intestine, colon, and
rectum. To identify differential expression signatures, we used
an unbiased univariate ﬁlter to select top-varying genes and
then applied Signiﬁcance Analysis of Microarrays20 (SAM) to
whole-genome expression data collected from biopsy tissue
samples and whole blood of individuals in the ustekinumab
trial. To control for multiple hypothesis testing, we used the
Benjamini & Hochberg adjustment on the raw P values to
control the family-wise error rate and set a false discovery rate
threshold of 1% or 5%. All analyses were performed using the
R statistical package, version 2.15.24.1
Bayesian network. We employed Monte Carlo Markov
Chain21 simulation to identify potentially thousands of different
plausible networks that are then combined to obtain a
consensus network. eSNP data were used as priors as follows:
genes with cis-eSNP22 are allowed to be parent nodes of genes
without cis-eSNPs, but genes without cis-eSNPs are not allowed
to be parents of genes with cis-eSNPs.
Key driver analysis. Key driver analysis takes as input a
set of genes (G) and a directed gene network (N) (eg, Bayesian
network).19,23–26 The objective is to identify the key regulators
for the gene sets with respect to the given network. Key driver
analysis ﬁrst generates a subnetwork NG, deﬁned as the set of
nodes in N that are no more than h-layers away from the nodes
in G, and then searches the h-layer neighborhood (h ¼ 1,..,H) for
each gene in NG (HLNg,h) for the optimal h*, such that
ES h ¼ max ð ES h; g Þc g ˛ N g; h ˛ f1 : : H g
where ESh,g is the computed enrichment statistic for HLNg,h. A
node becomes a candidate driver if its HLN is signiﬁcantly
enriched for the nodes in G. Candidate drivers without any
parent node (ie, root nodes in directed networks) are desig-
nated as global drivers, while the remaining are designated as
local drivers.
Pathway enrichment. Expression quantitative trait loci
(eQTL) analysis was performed on IBD, ulcerative colitis, and
Crohn’s disease genome-wide association study (GWAS) hits
from the National Human Genome Research Institute catalog,
plus all Wellcome Trust Case Control Consortium IBD GWAS
single nucleotide polymorphisms with P  .001. Ten percent
false discovery rate eGenes were thus extracted, and tested for
enrichment of pathways from the Metacore database.
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correlation to examine the relationship between the messenger
RNA expression of TRIM22 in intestine and blood and several
key IBD traits. The correlation test was performed with the R
function “corr.test.” We applied a simple Bonferroni correction
to a .01 signiﬁcance level across all gene-trait correlation tests
performed.
Transfection and luciferase reporter assays. NF-
kB luciferase reporter plasmids (Promega, Madison, WI) and
interferon-stimulated response element promoter and
interferon-beta promoter luciferase reporter plasmids were
obtained from Dr Hong-bing Shu (Wuhan University). A total of
HEK 293 cells (1  105) were seeded on 24-well dishes and
transfected the following day using Lipofectamine 2000
method. Empty control plasmid was added to ensure that each
transfection received the same amount of total DNA. To
normalize for transfection efﬁciency, 0.01 mg pRL-TK (Renilla
luciferase) reporter plasmid was added to each transfection.
Approximately 24 hours after transfection, luciferase assays
were performed using a dual-speciﬁc luciferase assay kit
(Promega). Fireﬂy luciferase activities were normalized on the
basis of Renilla luciferase activities. Cells were treated with
recombinant TNFa, respiratory syncytial virus (RSV), or
L18-muramyl dipeptide (MDP) (InvivoGen, San Diego, CA).
Statistical analysis of luciferase assay data consisted of 2-way
analysis of variance followed by Bonferroni post-hoc testing
to compare across conditions. Statistical signiﬁcance was
assigned to tests with P < .05 after Bonferroni correction.
Coimmunoprecipitation and immunoblot ana-
lysis. For transient transfection and coimmunoprecipitation
experiments, HEK 293 cells (1  106) were seeded for 24 hours
then transiently transfected for 18 to 24 hours using Lip-
ofectamine 2000 according to the manufacturer’s protocols.
Transfected cells were lysed in 1 mL lysis buffer (150 mM NaCl,
50 mM HEPES, 1% Triton X-100, 10% glycerol, 1.5 mM MgCl2,
1.0 mM ethylene glycol-bis[b-aminoethyl ether]-N,N,N0,N0-
tetraacetic acid) supplemented with protease and phosphatase
inhibitors (aprotinin, 1:1000; leupeptin, 1:1000; pepsin,
1:1000; and phenylmethylsulfonyl ﬂuoride, 1:100). For each
immunoprecipitation, a 0.9-mL aliquot of the lysate was incu-
bated with 0.5 mL of the indicated antibody and 40 mL of a 1:1
slurry of Protein G Sepharose (Bioshop, Burlington, ON, Can-
ada) for 1 hour. Sepharose beads were washed 3 with 1 mL
high salt lysis buffer containing 0.5 M NaCl. The precipitates
were analyzed by standard immunoblot procedures using the
following antibodies: mouse monoclonal anti-FLAG (Sigma, St
Louis, MA), anti-HA (Origene, Rockville, MD), anti-NOD2
(Novus), antigreen ﬂuorescent protein (Invitrogen, Carlsbad,
CA), rabbit polyclonal anti-TRIM22 (Abnova, Taipei City,
Tawain), and goat polyclonal anti-NOD2 (Ingenix). For endog-
enous coimmunoprecipitation experiments, HT29 cells (5 
107) were stimulated with MDP (10 mg/mL) for the indicated
times or left untreated. The coimmunoprecipitation and
immunoblot experiments were performed as described here.Results
Case History
Patient 1 was born in Australia to consanguineous par-
ents. She initially presented on day 8 of life with fever, oral
ulcers, diarrhea, and failure to thrive and later developedsevere ﬁstulizing perianal disease (Figure 1A) and granu-
lomatous colitis (Figure 1B). She deteriorated despite
treatment with corticosteroid and biologic therapy. Symp-
tomatic control was only achieved by fecal stream diversion
with combined ileostomy and subtotal colectomy. Patients 2
and 3 had a very similar clinical course, with granulomatous
colitis and severe perianal disease (Figure 1C and D)
requiring ileostomy followed by total proctocolectomy. Both
patients 2 and 3 presented with severe anemia and severe
hypoalbuminemia secondary to colitis. Patients 1 and 2
had numerous bacterial and viral infections. The 3 patients
did not have mutations in the IL10RA/B, IL10, XIAP, or
NOD2 genes, and were all very difﬁcult to treat medically
and surgically, with their disease nonresponsive to anti-
TNFa biologic therapy (Supplementary Table 1A; see
Supplementary Material for full clinical description).Whole Exome Sequencing
WES of patient 1 (and parents) resulted in >100 the
mean exome coverage and identiﬁed 152,020 variants,
including 16,097 rare variants (minor allelic frequency
<0.01) predicted to be damaging (Supplementary Figure 1).
From this list, we identiﬁed 12 nonsynonymous homozy-
gous variants (Supplementary Table 2) that were inherited
in an autosomal recessive manner. Based on known protein
function, expression proﬁles, animal models, mutation con-
servation, and network analysis. This list was narrowed
down to a single candidate gene—TRIM22. Patient 1 had a
homozygous nonsynonymous variant in exon 7 of the
TRIM22 gene inherited from both parents (Figure 1E). This
missense variant resulted in an arginine to cysteine
substitution (c.1324C>T; p.Arg442Cys) predicted to be
highly deleterious (Figure 1F and Supplementary Table 1B).
It is highly conserved in a functionally signiﬁcant region of
the exposed beta sheet around the variable loop 3 (V3) in
the B30.2 (SPRY) domain thought to be responsible for
subcellular localization27,28 and the 3-dimensional structure
suggest it results in an elongated or additional beta strand,
which in the wild type, forms a relaxed loop segment.
To validate, we examined WES from 150 VEOIBD
patients, but did not identify damaging variants in TRIM22.
Therefore, we performed targeted exome sequencing in 10
patients with a similar severe phenotype and identiﬁed 2
additional patients with TRIM22 variants (patients 2 and 3).
Patient 2 had compound heterozygous TRIM22 variants
(Figure 1E), including a novel arginine to threonine substi-
tution (c.449G>C, p.Arg150Thr) inherited paternally; and a
serine to leucine substitution (c.731C>T; p.Ser244Leu)
inherited maternally. Both variants were predicted to be
damaging and to disrupt the highly conserved coiled-coil
region of TRIM22 that facilitates homodimer/heterodimer
multimers (Figures 1F, Supplementary Figure 2, and
Supplementary Table 1B). R150T is in an exposed region
and S244L is buried and resides in the spacer-2 region that
contains a bipartite nuclear localization sequence, and was
previously predicted to be a serine phosphorylation site.27
Patient 3 had a homozygous TRIM22 variant inherited
from both parents (Figure 1E). This nonsynonymous variant
Figure 1. Clinical features
and pedigrees of patients
with TRIM22 variants. (A,
B) Clinical presentation
and histopathologic ﬁnd-
ings in colonic biopsy from
patient 1. (A) Severe peri-
anal ﬁstulization with seton
placement. Rectovaginal
ﬁstulae were also present.
(B) Non-caseating granu-
lomas on a background of
chronic inﬂammatory cell
inﬁltrates (H&E stain). (C,
D) Clinical presentation
and histopathologic ﬁnd-
ings in colonic biopsy from
patient 2. (C) Multiple, se-
vere cavitating perianal
ﬁstulae. (D) Colonic biopsy
showing chronic inﬂam-
mation with non-caseating
granuloma (black arrow)
(H&E stain, scale bar ¼ 75
mm). (E) Pedigree analysis
of the genetic inheritance
pattern for each family trio.
(F) Schematic view of the
protein domain architec-
ture of TRIM22 with the
relative position of each
identiﬁed variant depicted.
Number indicates amino
acid position.
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c.962G>A). The R321K variant was predicted to be delete-
rious and located in the highly conserved SPRY domain on
an exposed residue of a beta sheet that has a functional role
in the antiviral activity patch of the SPRY domain27
(Figure 1F, Supplementary Table 1B).Integrative Analysis Supports TRIM22 as
a Key Regulator in Inﬂammatory Bowel
DiseaseAssociated Networks
To gain insight into the role of TRIM22 in the pathogen-
esis of IBD, we constructed a probabilistic causal networkmodel by integrating 7,568 RNA-sequencederived gene
expression traits from ileal biopsies from 322 treatment-
naïve pediatric Crohn’s patients in the RISK cohort19 and
eQTL. To identify the VEOIBD component of this molecular
network, we projected all genes known to be causally
associated with VEOIBD9 (Supplementary Table 3) onto this
network, and then identiﬁed the most connected subnet-
work containing these VEOIBD genes within the full RISK
network, resulting in the VEOIBD network composed of 665
genes, which included TRIM22 (Figure 2A).
To understand the regulation of this VEOIBD network, we
employed a previously established procedure26 to identify key
regulator genes that are predicted tomodulate the state of the
1200 Li et al Gastroenterology Vol. 150, No. 5
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signiﬁcant key regulators identiﬁed in the VEOIBD network
included SNX10, STX11, CYBB, and DRAM1, which directlyconnect TRIM22 to the IBD gene NOD2 via 2 equidistant
paths. The ﬁrst pathway, TRIM22/SNX10/STX11/
DRAM1/NOD2, is linked to the known VEOIBD gene STAT1
Figure 3. TRIM22 interacts with and activates NOD2 signaling. (A) Endogenous NOD2 and TRIM22 co-immunoprecipitate after
MDP stimulation. HT29 cells were stimulated with MDP (1 mg/mL) for various time periods. After treatment, cells were lysed and
endogenous TRIM22was immunoprecipitated using anti-TRIM22 antibody conjugated to Protein G-Sepharose. Bound levels of
endogenous NOD2 were evaluated using Western blotting. As stimulation time with MDP increased, the binding of endogenous
NOD2 to TRIM22 increased. Immunoprecipitation with IgG bound to Protein G-Sepharose was used as a negative immuno-
precipiation control. (B) TRIM22 interacts with NOD2. HEK293T cells were transiently cotransfected with HA-NOD2 and either
wild-type (WT) or variant (R150T, S244L, R321K, and R442C) FLAG-epitope tagged TRIM22. Twenty-four hours post trans-
fection, cells were lysed followed by immunoprecipitation of the FLAG-TRIM22 by anti-FLAG-agarose. Reduced binding of
NOD2 to TRIM22 was observed in varying degrees for each variant compared to theWT protein. HA-NOD1 and an empty vector
construct were used as negative controls. (C) Quantiﬁcation of NOD2 co-immunoprecipitation with WT or mutant TRIM22.
Densitometry analysis was performed on Western blots performed in (B). Each TRIM22 point mutation signiﬁcantly reduced
NOD2 co-immunoprecipitation (Student’s t test, *P < .05; **P < .01, n ¼ 3). (D) TRIM22 mutants fail to activate NF-kB and
interferon-beta downstream of NOD2. HCT116 cells were transiently co-transfected with (or without) NOD2, TRIM22-WT, or
TRIM22 point mutants (R150T, S244L, R321K, R442C). Twenty-four hours post transfection, cells were stimulated with either
MDP (10 mg/mL) or RSV (0.1 mg) for 18 hours before NF-kB or interferon-beta promoter activation was evaluated by luciferase
assay. Cells transfected with TRIM22mutants showed signiﬁcantly reduced NF-kB and interferon-beta promoter activation after
stimulation compared with WT TRIM22 transfected controls (*P < .001 after Bonferroni post-hoc testing, n ¼ 3).
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TRIM22/SNX10/CYBB/DRAM1/NOD2, contains the
known VEOIBD gene CYBB (Figure 2B). Both STAT1 and CYBB,
in addition to IRF8, which is directly connected to TRIM22, are=
Figure 2. TRIM22-NOD2 network. (A) VEOIBD loci-focused subn
the context of VEOIBD in the ileum network, genes known to be
projected onto the RISK network and extended out a path length
of 665 genes and contains TRIM22 and NOD2. The TRIM22-N
known VEOIBD loci CYBB and STAT1, as well as the GWAS lo
TRIM22 paths in the 665-node VEOIBD focused subnetwork. Re
the 665 node VEOIBD loci focused RISK subnetwork. (C) TRIM
This network provides the context of the TRIM22-NOD2 interac
was projected and extended out an additional path length on the
VEOIBD loci (orange), IBD drug targets approved or in clinical
represented in this conserved subnetwork.associated with Mendelian susceptibility to mycobacteria
deﬁciency.29 As expected, we did not identify any common
DNA variants from the International Inﬂammatory Bowel
DiseaseGenetics ConsortiumGWAS30within theTRIM22 locusetwork within RISK Pediatric Crohn’s ileum network. To deﬁne
causally associated with VEOIBD (not including TRIM22) were
of 2. The resulting VEOIBD focused subnetwork is composed
OD2 paths are highlighted in bold and are connected to the
cus IRF8. (B) Local network structure surrounding the NOD2/
presentative nodes from the 179-gene TRIM22 network within
22-NOD2 interaction is conserved in the adult IBD intestine.
tion in the adult IBD intestine. The 179-gene TRIM22 network
adult IBD pan intestine Bayesian network. IBD GWAS (green),
development (red), and calprotectin (S100A8) (purple) are all
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network is well represented in genes involved in TRIM22-
relevant pathways, including p53, ubiquitin response, and
antiviral signaling, which were among the top pathways
enriched for genes associated with intestine and blood eQTL
that were also associated with adult IBD loci identiﬁed in the
International Inﬂammatory Bowel Disease Genetics Con-
sortium cohort (Supplementary Figure 3, Supplementary
Table 7). In addition, we found that the VEOIBD network
was 2.1-fold enriched (P ¼ 2.3 e-5) for Crohn’s genes anno-
tated fromadult IBDgenetic studies that also give rise to blood
eQTLs31 (Supplementary Table 8).Adult-Onset Inﬂammatory Bowel Disease
Informed by a TRIM22-Centered Network
Given preliminary support for adult IBD in the VEOIBD
network, we explored whether the TRIM22 component of
the VEOIBD network was associated with adult IBD. We
constructed an adult IBD causal gene network from gene
expression and genotype data generated on 203 intestinal
biopsies, which included inﬂamed and noninﬂamed tissues
from ileum, ascending colon, descending colon, transverse
colon, sigmoid, and rectum. All of these tissues, in addition
to blood, were collected at baseline from 54 anti-
TNFaresistant Crohn’s patients enrolled in the
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trial18 (Supplementary Figure 4). We found that TRIM22
was not only a key driver gene in the sigmoid (key driver p
¼ 4.0e-06) and rectum (key driver P ¼ 1.0e-4) networks,
but it was signiﬁcantly upregulated in inﬂamed sigmoid
(fold change ¼ 2.47, SAM-based p ¼ 6.31e-05) and inﬂamed
rectum (fold change ¼ 2.39, SAM-based P ¼ 5.03 e-06),
compared with non-inﬂamed samples of these same tissues.
We identiﬁed the homologous TRIM22 component of the
adult IBD network by ﬁrst identifying all genes within a path
length of 5 to TRIM22 in the VEOIBD network, which
included NOD2, leaving a network composed of 179 genes
(referred to here as the TRIM22 network; Supplementary
Table 9). This TRIM22 network contained many
macrophage/monocyte-expressed genes associated with
mycobacterial and antiviral responses (including genes
involved in autophagy, NF-kB pathway, and apoptosis;
Supplementary Figure 5; Supplementary Table 10). Strik-
ingly, of the 480 key driver genes we identiﬁed in the adult
IBD network, 62, including STX11, CYBB, and DRAM1, were
represented in the pediatric TRIM22 network, 7.2-fold
enrichment over what is expected by chance (P ¼ 6.5
e-38) (Supplementary Table 11). Further, the TRIM22 con-
taining co-expression module from the blood of ustekinu-
mab patients, which was 12.7-fold enriched for response to
virus (P ¼ 6.3e-14), was 9-fold enriched in the pediatric
TRIM22 network (P < 1e-16). Further supporting the pe-
diatric TRIM22 network’s association to viral response was
a 3.2-fold enrichment (P ¼ 2.5e-5) of eQTLs associated with
dendritic cell response to stimulation with ﬂu or interferon
beta32 and an 8.3-fold enrichment (P ¼ 1.1e-16) of genes in
a tuberculosis infection signature in dendritic cells.30
The homologous TRIM22 network in the adult IBD
network was then identiﬁed by projecting nodes from the=
Figure 4. TRIM22 mediates K63-linked NOD2 polyubiquitinatio
cells. HEK293T cells were transiently co-transfected with HA-NO
type (WT) or variant (R442C) FLAG-TRIM22. Twenty-four hours
cipitation of HA-NOD2. Ubiquitination of NOD2 was evaluated b
TRIM22 enhanced ubiquitination of NOD2, which was abrogated
out in triplicate, independent experiments. (B) Transgenic TRIM
cells. HT29 cells stably transduced with control (scramble) o
transfected with HA-NOD2 and either WT or variant (R442C
were lysed followed by immunoprecipitation of the HA-NOD2. E
demonstrated rescued ubiquitination after transfection of WT-T
after transfection of the variant R442C. All experiments were ca
TRIM22 abrogates K63-linked NOD2 polyubiquitination. HEK29
(K63-speciﬁc) ubiquitin, and either WT or variant (R150T, S24
transfection, cells were lysed followed by immunoprecipitatio
ubiquitination by HA immunoblotting demonstrated signiﬁcant
variants compared to WT. All experiments were carried out in
reduces MDP- and RSV-induced K63-linked NOD2 polyubi
(scramble) or TRIM22 shRNA were transfected with HA-tagged K
transfection, cell lysates were stimulated by MDP (D) or RSV (
noprecipitation using anti-FLAG-agarose. K63-poly-ubiquinatio
antibody. After stimulation by either MDP or RSV, NOD2 K63-s
er, in TRIM22 knockdown cells, this ubiquitination was signiﬁc
triplicate independent experiments and blots are representative
and its identiﬁed variants on the NOD2 signaling axis. WT TRIM
NOD2, potentiating downstream signaling through the MAVS a
iants disrupt binding to NOD2, abrogating this polyubiquinationTRIM22 network onto the adult IBD network, identifying
those nodes that were either in the TRIM22 network or
directly connected to such nodes (Figure 2C). In this TRIM22
pediatric-oriented adult IBD network, TRIM22 is in close
proximity to several drug targets that are either approved
or in clinical development for IBD, including TNFa, the
target of adalimumab (Humira), certolizumab (Cimzia),
inﬂiximab (Remicade), and colimumab (Simponi); IL12Rb, a
chain shared between the receptors that bind IL12/23, the
molecular target of ustekinumab; JAK3, the target of tofa-
citinib; and IL17RA, the target of brodalumab.
Because S100A8 (calprotectin), a stool biomarker for
inﬂammation, is also co-localized with TRIM22 in this
network33–35 (Figure 2C), we decided to further investigate
the role of TRIM22 in treatment-refractory patients,
exploring associations between TRIM22 and IBD-associated
clinical traits in the ustekinumab clinical trial
(Supplementary Table 12). We found that expression levels
of TRIM22 in the colon were positively correlated with fecal
calprotectin regardless of biopsy inﬂammation status.
Overall, both inﬂamed and noninﬂamed baseline intestine
levels of TRIM22 revealed a correlation to blood C-reactive
protein, of which consistently high levels are associated
with subsequent development of perianal ﬁstulae in Crohn’s
patients36 and response to anti-TNFa.37 TRIM22 expression
levels in blood were positively correlated with Crohn’s
Disease Activity Index (Supplementary Table 13).
Taken together, the intestinal network models provide
causal support for the TRIM22 regulation of NOD2 and the
correlation of the TRIM22-NOD2 pathway with predicted
disease regulators, functionally relevant VEO and adult-
onset IBD genetic loci, effectors of antiviral and mycobac-
terial function, correlation with inﬂammatory clinical
variables and validated IBD drug targets.n. (A) TRIM22 enhances NOD2 polyubiquitination in HEK293
D2, green ﬂuorescent protein (GFP) ubiquitin, and either wild-
post transfection, cells were lysed followed by immunopre-
y immunoblotting for GFP (ubiquitin). Co-transfection with WT
with the R442C variant TRIM22. All experiments were carried
22 rescues NOD2 polyubiquitination in TRIM22-shRNA-HT29
r TRIM22 short-hairpin RNA (shRNA) were transiently co-
) FLAG-TRIM22. Twenty-four hours post transfection, cells
valuation of NOD2 poly-ubiquitination by GFP immunoblotting
RIM22 in the TRIM22 shRNA cell line that was not observed
rried out in triplicate, independent experiments. (C) Variants in
3T cells were transiently cotransfected with FLAG-NOD2, HA-
4L, R321K, or R442C) V5-TRIM22. Twenty-four hours post
n of the FLAG-NOD2. Evaluation of NOD2 K63 speciﬁc-
ly reduced ubiquitination in cells cotransfected with TRIM22
triplicate, independent experiments. (D, E) TRIM22-shRNA
quitination. HEK293T cells stably transduced with control
63-speciﬁc ubiquitin and FLAG-NOD2. Forty-eight hours after
E) for indicated the time points, followed by lysis and immu-
n of NOD2 was evaluated by immunoblotting using anti-HA
peciﬁc ubiquitination increased over treatment time. Howev-
antly reduced or absent. All experiments were carried out in
. (F) Schematic overview of the proposed impact of TRIM22
22 binds and mediates the K63-speciﬁc polyubiquitination of
nd RIPK2 signaling axes depending on antigen. TRIM22 var-
thus attenuating downstream pro-inﬂammatory signaling.
1204 Li et al Gastroenterology Vol. 150, No. 5
BASIC
AND
TRANSLATIONAL
ATIdentiﬁcation of TRIM22 as a NOD2
Interacting Protein
As NOD2 signaling plays a critical role in Crohn’s disease
susceptibility38,39; we further investigated this in silico
TRIM22NOD2 interaction. Immunoﬂuorescence showed
that NOD2 and TRIM22 colocalized in colonic biopsies and
in the cytoplasm of transient transfected HEK293 cells
(Supplementary Figure 6A–C). This NOD2 immunostaining
was blocked by a NOD2-speciﬁc peptide and TRIM22 did
not colocalize with NOD1 (Supplementary Figure 6D–F),
another member of the NOD family, conﬁrming the speci-
ﬁcity of this TRIM22NOD2 interaction. Immunostaining of
colonic biopsy samples from patients 13 with TRIM22
variants showed altered expression and localization of
NOD2 and TRIM22 (Supplementary Figure 6A and B).
TRIM22 Inﬂuences NOD2 Signaling Pathways
NOD2 senses MDP, a conserved structure in peptido-
glycan present in most Gram-negative and Gram-positive
bacteria. We found that TRIM22 was weakly associated
with endogenous NOD2 in coimmunoprecipitation experi-
ments in unstimulated HT29 cells, a human intestinal
epithelial cell line, and this association increased after
stimulation with MDP (Figure 3A). Furthermore, transiently
transfected TRIM22 and NOD2 were found to reciprocally
coimmunoprecipitate and these interactions were reduced
with the TRIM22 variants (Figure 3B and C and
Supplementary Figure 7A).
Because TRIM22 colocalized and coimmunoprecipitated
with NOD2, we next determined whether TRIM22 inﬂu-
enced MDP-induced NF-kB signaling via NOD2. In reporter
assays, coexpression of TRIM22 and NOD2 enhanced MDP-
induced activation of the NF-kB (Figure 3D) in HEK293 cells.
As TRIM22 regulates viral activity15–17 and NOD2 functions
as cytoplasmic viral pathogen recognition receptor by trig-
gering interferon-beta activation in response to RSV,40,41 we
next determined whether TRIM22 also regulated NOD2-
dependent RSV-induced interferon-beta signaling. As
shown in Figure 3D, overexpression of TRIM22 and NOD2
both enhanced RSV-induced activation of the interferon-
beta promoter and the interferon-stimulated response
element. Neither wild-type TRIM22 nor the TRIM22-R442C
variant enhanced TNFa gene expression in response to
TNFa (Supplementary Figure 7B). As TNFa activates NF-kB
target genes independent of NOD2 signaling,42 this sug-
gested that TRIM22 regulation of MDP-induced NF-kB acti-
vation is NOD2-dependent.
TRIM22 Variants Inﬂuence NOD2 Signaling
We next examined the role of TRIM22 to regulate NOD2-
dependent NF-kB and interferon-beta signaling. Luciferase
assays using HEK293 cells and real-time polymerase chain
reaction experiments using HCT116 showed that expression
of wild-type TRIM22 potentiated NOD2 signaling in
response to both MDP-induced NF-kB and RSV-induced
interferon-beta activation (Figures 3D and Supplementary
Figures 7C–F). However, the TRIM22 variants (Figures 3D
and Supplementary Figures 7C–E) and TRIM22 knockdownusing short-hairpin RNA (Supplementary Figure 8A) showed
impaired NOD2-dependent NF-kB and interferon-beta
signaling (Supplementary Figure 8B). MDP-mediated
NOD2-dependent signaling was also signiﬁcantly reduced
in patient 2 only, with the heterozygous TRIM22 variants in
the coiled-coil domain (Supplementary Figure 9 and
Supplementary Material). Together, these data suggest that
TRIM22 is a positive regulator of antiviral and antibacterial
NOD2-dependent signaling pathways.TRIM22 Mediates K63-Linked
Polyubiquitination of NOD2
As TRIM22 is a RING ﬁnger E3 ubiquitin ligase11 and
NOD2 has high conﬁdence predicted ubiquitination sites at
K436 and K445 (CKSAAP_UbSITE43), we next determined
whether TRIM22 mediated ubiquitination of NOD2. Immu-
noprecipitation experiments using a HEK293 cell line
co-expressing HA-NOD2 and Flag-TRIM22 showed that
overexpression of TRIM22 enhanced NOD2 poly-
ubiquitination (Figure 4A). The TRIM22 variants (Figure 4A
and Supplementary Figure 10A) were unable to mediate this
NOD2 polyubiquitination. TRIM22 did not increase poly-
ubiquitination of other components (MAVS or RIPK2) of the
NOD2 signaling pathways known to be ubiquitinated44,45
(Supplementary Figure 10B). Using the TRIM22 short-
hairpin RNA HT29 stable cell line, we found that only
wild-type TRIM22 rescued NOD2 polyubiquitination and
not the TRIM22-R442C variant (Figure 4B). Taken together,
this suggested that TRIM22 speciﬁcally mediates NOD2
polyubiquitination.
K63-linked polyubiquitination regulates the localization
and signaling activity, whereas K48-linked poly-
ubiquitination often mediates degradation.46 NOD2 has
been previously shown to be K48-linked ubiquitinated by
TRIM27 and results in NOD2 degradation.47 Using ubiquitin
mutants, we showed that overexpression of TRIM22 medi-
ated K63-linked but not K48-linked polyubiquitination of
NOD2, while the TRIM22 variants were unable to mediate
K63- or K48-linked NOD2 polyubiquitination (Figure 4C and
Supplementary Figure 11A). We next determined that
TRIM22 is required for MDP- and RSV-induced K63-linked
NOD2 polyubiquitination and knockdown of TRIM22
reduced this MDP- and RSV-induced K63-linked (Figure 4D
and E), but not K48-linked NOD2 polyubiquitination
(Supplementary Figures 11B and C).Discussion
TRIM proteins are involved in a number of biologic
processes, including cell proliferation, apoptosis, innate
immunity, autoimmunity, and inﬂammatory response.48,49
Variants in TRIM genes result in monogenic diseases,
including familial Mediterranean fever and Opitz syndrome
type 1, and are implicated in a number of cancers and
autoimmune diseases, including multiple sclerosis, rheu-
matoid arthritis, and systemic lupus erythematosus.48,49
TRIM22 belongs to a subfamily of TRIM proteins that
contain a SPRY domain and are thought to have evolved to
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the SPRY domain of TRIM20 (pyrin) result in autoimmune
diseases, including familial Mediterranean fever.50 Over-
expression of TRIM22 is known to activate NF-kB in a dose-
dependent manner and both the N-terminal RING domain
and C-terminal SPRY domain are crucial for TRIM22-
mediated NF-kB activation13 and antiviral activity,15–17
and are implicated in the pathogenesis of autoimmune dis-
eases.51 Patients 1 and 3 both had homozygous variants in
the SPRY domain and patient 2 had compound heterozygous
variants both predicted to disrupt the coiled-coil domain
and had loss of NOD2-dependent MDP signaling. The char-
acterized TRIM22 variants resulted in impaired NOD2
binding and K63-linked NOD2 polyubiquitination. The pre-
dicted NOD2 polyubiquitination sites described earlier are
in the NACHT domain, a conserved domain required for
NOD2 conformational change in response to MDP sensing
through the LRR domain or interaction with binding adaptor
proteins for NOD2.52 Therefore, as all identiﬁed TRIM22
variants disrupt both NOD2-dependent NF-kB and
interferon-beta signaling, this suggests that K63-linked
polyubiquitination of NOD2 meditated by TRIM22 is crit-
ical for NOD2 function (Figure 4F).
NOD2 has long been recognized as a critical player in
Crohn’s disease pathogenesis,38,39 where it is proposed to
regulate innate immunity through NF-kBinduced pro-
inﬂammatory responses triggered by peptidoglycan
(reviewed in Shaw et al53). Numerous studies have shown
that the loss of function variants in NOD2 associated with
Crohn’s disease result in the loss of NF-kB induced pro-
inﬂammatory cytokine response to MDP (reviewed in
Strober et al54 and Philpott et al55) and, therefore, mirror
the defect we observe in patient 2 with TRIM22 mutations
in the coiled-coil domain. Similarly, mutations in XIAP (also
an E3 ubiquitin ligase) are associated with IBD with gran-
ulomatous colitis and perianal disease56,57 and are associ-
ated with loss of NOD2-dependent mediated NF-kB
signaling58–60 and XIAP is also regulated by TRIM pro-
teins.61 XIAP deﬁciency usually presents in early childhood,
but there are cases of patients presenting with IBD at older
than 40 years of age9 with and without hemophagocytic
lymphohistiocytosis (reviewed in Latour and Aguilar62).
Furthermore, XIAP not only regulates NOD2-dependent
innate immunity responses, but also is proposed to regu-
late inﬂammasome and adaptive immunity.62 Loss-of-
function NOD2 variants associated with IBD have low
penetrance and do not cause the severe early-onset disease
observed in this group with either TRIM22 or XIAP deﬁ-
ciency. Therefore, it is most likely that, in patients 1 and 3
with TRIM22 SPRY domain variants, defects in other path-
ways regulated by TRIM22 result in the early onset and
severity of disease. Alternatively, hypomorphic TRIM22
variants act in an oligogenic manner with mutations in other
genes similar to what has been observed with hypomorphic
XIAP mutations63 and as observed in patient 3, who is also a
carrier of a XIAP mutation. Together, this suggests that loss
of NOD2-dependentmediated signaling in response to
MDP contributes to a severe form of IBD and that other yet
deﬁned pathways must also be involved in diseasepathogenesis. With regard to TRIM22 speciﬁcally, we
anticipate that other pathways not identiﬁed in these
studies play a role in disease pathogenesis.
Our computational studies further support our functional
studies demonstrating that TRIM22 inﬂuences both NOD2-
dependent interferon-beta and NF-kB signaling pathways.
Although the loss-of-function TRIM22 variants in our VEOIBD
patients can manifest as an immunodeﬁciency, the inﬂam-
mation and tissue damage that ensues from a dysregulated
response to microbial burden might resemble the proﬁle of
adult-onset IBD. The functional outcome of pro-inﬂammatory
NF-kB activation may differ, depending on the cell population
in which TRIM22 is expressed, with circulating plasmacytoid
dendritic cells andmonocytes predominating in the blood and
resident intestinal dendritic cells, macrophages, and enter-
ocytes in the intestine. We see from the intestine network that
the regulation of causal TRIM22 results in modulation of a
mycobacterial and viral response subnetwork that can also
result in feedback to TRIM22 expression. Either due to
immunodeﬁciency arising from the TRIM22 variants or
excessive inﬂammation in non-TRIM22 variants carried by
anti-TNFa refractory patients, TRIM22-driven NOD2 activa-
tion in response to MDP or viral stimuli, contributes to dys-
regulation of NF-kB and interferon-betadriven pathways
as reﬂected in the networks. Together, this demonstrates that
the TRIM22-NOD2 network plays a critical role in the devel-
opment of IBD.
Investigation of VEO and adult-onset IBD in treatment
refractory disease will elucidate new treatment opportu-
nities by revealing complexity of disease network dysregu-
lation. Causal- and correlative-based network analysis
allows for consideration of the synergistic effects between
genes in disease, which can be a greater determinant than
evaluation of single target genes to inform disease drivers
and opportunities for combinatorial therapy. Network
analysis can be focused by novel variants, as seen with
TRIM22 identiﬁed through WES in VEOIBD patients to
generate hypothesis and potentially identify biomarkers and
guide drug discovery and repositioning in both VEO and
adult-onset IBD patient subsets.
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